Ambroise M.
- Country
- France
- Department
- Hematology
Research Overview
- Evaluation of Blinatumomab, Isatuximab, and Ponatinib in Frontline Therapy for Adults with Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
- An ALFA 2101 multicenter randomized phase II study: CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics
- Phase II Evaluation of Glofitamab and Obinutuzumab in Relapsed/Refractory Lymphomas Post Anti-CD19 CAR T-Cell Therapy
Data & Insights
Has run more than one trial at 49 of 119 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), with particular expertise in novel therapeutic approaches for these conditions.
- Advanced Treatment Protocols
- Genomic Risk Stratification
- Therapeutic Response Assessment
Their work extends to evaluating innovative drug combinations and treatment strategies for refractory cases.
Transplantation Medicine
Focuses on allogeneic stem cell transplantation techniques and the prevention of post-transplant complications, including innovative approaches using fecal microbiota transplantation.
- Graft-versus-Host Disease Prevention
- Reduced Intensity Conditioning
- Donor Matching Optimization
Expertise includes developing protocols for both autologous and allogeneic transplantation procedures.
Lymphoma Research
Specializes in treating peripheral T-cell lymphoma and refractory lymphomas, with emphasis on innovative therapeutic approaches including bispecific antibodies.
- CAR T-cell Therapy
- Targeted Immunotherapy
- Response Assessment Protocols
Investigates novel treatment strategies for patients with relapsed or resistant disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.